Dexcom G6: Predictive Urgent Low Soon Alert 26 August 2024 Advertisement ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. Read the warnings available on dexcom.com/downloadsandguides before purchasing. Consult your healthcare professional to see if this product is right for you. Living with type 1 diabetes is challenging, but with the Dexcom G6 Continuous Glucose Monitoring (CGM) system, the Urgent Low Soon Alert lets you know when your glucose is falling so fast it will drop to 3.1 mmol/L in less than 20 minutes. This gives you time to prevent yourself from going too low. The Dexcom G6 is indicated for people with type 1, type 2 and gestational diabetes**, and sets the global standard as the first integrated CGM system to work together with t:slim X2™ insulin pump and integrated diabetes management apps like Glooko. Experience the Dexcom Difference: CUSTOMISABLE ALERTS Urgent Low Soon Alert – know before you’re low NO FINGERPRICKS^ Provides you the freedom of zero fingerpricks^ and no calibration ^If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions SHARE YOUR GLUCOSE DATA Easily share your glucose data with your loved ones via the Follow app¶, or store and share ongoing data with your healthcare team via Dexcom Clarity CONNECTED Multiple viewing options such as your smartphone,* optional Dexcom receiver, or t:slim X2 insulin pump†, allowing you to monitor your way OUTSTANDING ACCURACY1 Make confident treatment decisions even when glucose is changing rapidly Who can benefit from Dexcom G6? Anyone 2 years and over with type 1, type 2 and gestational diabetes** can benefit from CGM It works whether you are using multiple daily injections or an insulin pump To learn more about the Dexcom G6 CGM system, visit here: Dexcom Continuous Glucose Monitoring | Dexcom Curious to learn more about CGM? If you’re new to CGM and want to learn more about a specific Dexcom product, or curious about the features and benefits of real-time CGM, check out the Learn section on the Dexcom website. We’re here to support you along your way to better diabetes management with our self-guided training program. Discover education resources, training videos, and FAQs that will help you get the most out of your Dexcom CGM. Get your Dexcom G6 today! Dexcom G6 is subsidised for Australians living with type 1 diabetes. To learn more and check eligibility criteria visit Dexcom.com Not eligible for subsidy? Explore our flexible pricing options via our online shop. Disclaimers & references: **The product is indicated for persons with diabetes mellitus age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated. ^If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. ¶Do not make treatment decisions based upon Share and Follow readings. Always confirm with your compatible smart device or Receiver. Internet connectivity required to access Dexcom Follow. *Display devices sold separately. For a list of compatible smart devices, please visit dexcom.com/compatibility. †The Dexcom G6 CGM transmitter can only be paired with one medical device (either a Dexcom Receiver or t:slim X2 insulin pump) and one compatible smart device (phone or tablet) at the same time. For a list of compatible devices, please visit dexcom.com/compatibility. 1. Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018;20(6):395-402. Dexcom Inc. Dexcom, Dexcom Follow, Dexcom G6, Dexcom Share, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. This product is a continuous glucose monitoring system indicated for the management of (type 1, type 2, gestational) diabetes in people age 2 years and older where self-monitoring of blood glucose (SMBG) is indicated. ©2024 Dexcom, Inc. All rights reserved. AMSL is a Dexcom company. MAT-3675 Rev001 June 2024
Media releases 4 September 2024 New Australian Diabetes Clinical Trials Network will change lives Image: (L-R) Keren Pointon, Dr Lisa Hayes, Dr Anish Menon, Prof Elif Ekinci, Justine Cain, Susan Kozij, Prof David O’Neal,... Continue Reading
Blog 3 September 2024 Create a lasting legacy with the ultimate gift Diabetes Australia is at the forefront of supporting people living with all types of diabetes, providing essential support, services, education,... Continue Reading
Blog 3 September 2024 Is there a ‘best’ diet for diabetes? Various diets are recommended for individuals with diabetes, each with its unique benefits and potential drawbacks. Here, we explore some of the most popular dietary approaches for diabetes management. Continue Reading